

	Type	L #	Hits	Search Text	DBs	Time Stamp	Comments	Error Definition	Errors
1	BRS	L1	3383	(insulin-like adj growth adj factor-1) or IGF-1	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/01/27 16:10			0
2	BRS	L2	8	(composition same ((insulin-like adj growth adj factor-1) or IGF-1)) same solubilizing	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/01/27 16:10			0
3	BRS	L3	28	(composition same ((insulin-like adj growth adj factor-1) or IGF-1)) same (arginine or guanidinium or guanidine)	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/01/27 16:11			0
4	BRS	L4	747	"12" adj mg/ml	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/01/27 16:12			0
5	BRS	L5	16728	pH adj 5.5	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/01/27 16:12			0
6	BRS	L6	60028	arginine or (guanidine adj hydrochloride) or N-acetyl-arginine or guanidinium	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/01/27 16:13			0
7	BRS	L7	501	solubilizing adj compound	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/01/27 16:14			0

	Type	L #	Hits	Search Text	DBs	Time Stamp	Comments	Error Definition	Errors
8	BRS	L8	2260	"200" adj mg/ml	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/01/27 16:17			0
9	BRS	L9	7	(2 or 3) same 5	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/01/27 16:50			0
10	BRS	L10	3	(2 or 3) same pH same mg/ml	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/01/27 16:48			0
11	BRS	L11	261839	(glutamic adj acid) or (maleic adj acid) or (succinic adj acid) or (citric adj acid) or imidazole or histidine	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/01/27 16:49			0
12	BRS	L12	18573	11 same buffer	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/01/27 16:50			0
13	BRS	L13	2	(2 or 3) same pH same 12	USPAT; US-PGPUB; EPO; JPO; DERWENT	2004/01/27 16:50			0

=> d his

(FILE 'HOME' ENTERED AT 17:12:44 ON 27 JAN 2004)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA' ENTERED AT  
17:13:39 ON 27 JAN 2004

L1 86011 S (INSULIN-LIKE GROWTH FACTOR-1) OR IGF-I  
L2 3034 S COMPOSITION (P) L1  
L3 73 S SOLUBILIZING COMPOUND  
L4 368475 S ARGININE OR (GUANIDINE HYDROCHLORIDE) OR N-ACETYL-ARGININE OR  
L5 1 S L2 (P) L4 (P) SOLUBILIZING  
L6 1 S L2 (P) L3  
L7 0 S L6 NOT L5  
L8 0 S L2 (P) PH (P) MG/ML  
L9 1 S BUFFER (P) PH (P) L2  
L10 1 S L9 NOT L5  
L11 450482 S (GLUTARIC ACID) OR (MALEIC ACID)OR (SUCCINIC ACID) OR (CITRIC  
L12 11680 S L11 (P) BUFFER  
L13 1 S L2 (P) L12  
L14 1 S L13 NOT L9  
L15 0 S L14 NOT L5  
L16 328 S SHIRLEY B?/AU  
L17 40 S BAJWA K?/AU  
L18 2 S (L16 OR L17) AND L2  
L19 2 DUPLICATE REMOVE L18 (0 DUPLICATES REMOVED)

=> log y

FILE 'MEDLINE' ENTERED AT 17:13:39 ON 27 JAN 2004

FILE 'CAPLUS' ENTERED AT 17:13:39 ON 27 JAN 2004  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 17:13:39 ON 27 JAN 2004  
COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'EMBASE' ENTERED AT 17:13:39 ON 27 JAN 2004  
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'SCISEARCH' ENTERED AT 17:13:39 ON 27 JAN 2004  
COPYRIGHT 2004 THOMSON ISI

FILE 'AGRICOLA' ENTERED AT 17:13:39 ON 27 JAN 2004

=> s (insulin-like growth factor-1 or IGF-I  
UNMATCHED LEFT PARENTHESIS '(INSULIN-LI'  
The number of right parentheses in a query must be equal to the  
number of left parentheses.

=> s (insulin-like growth factor-1) or IGF-I  
5 FILES SEARCHED...  
L1 86011 (INSULIN-LIKE GROWTH FACTOR-1) OR IGF-I

=> s composition (p) l1  
L2 3034 COMPOSITION (P) L1

=> s solubilizing compound  
L3 73 SOLUBILIZING COMPOUND

=> s arginine or (guanidine hydrochloride) or N-acetyl-arginine or guanidinium  
L4 368475 ARGININE OR (GUANIDINE HYDROCHLORIDE) OR N-ACETYL-ARGININE OR  
GUANIDINIUM

=> s l2 (p) l4 (p) solubilizing  
L5 1 L2 (P) L4 (P) SOLUBILIZING

=> d l5 1 ibib abs

L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1999:325815 CAPLUS  
DOCUMENT NUMBER: 130:343031  
TITLE: Compositions providing for increased IGF-I solubility  
INVENTOR(S): Shirley, Bret A.; Bajwa, Kamaljit  
PATENT ASSIGNEE(S): Chiron Corporation, USA  
SOURCE: PCT Int. Appl., 32 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 3  
PATENT INFORMATION:

PATENT NO.    KIND   DATE    APPLICATION NO.   DATE

WO 9924063    A1   19990520    WO 1998-US23673   19981106

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ,  
CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU,  
ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV,  
MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,  
SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ,  
BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,  
FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,  
CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 9915193    A1   19990531    AU 1999-15193   19981106

EP 1028748    A1   20000823    EP 1998-959383   19981106

EP 1028748    B1   20030502

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, FI

JP 2001522814   T2   20011120    JP 2000-520151   19981106

AT 238807    E   20030515    AT 1998-959383   19981106

PRIORITY APPLN. INFO.:    US 1997-64891P   P   19971107

WO 1998-US23673   W   19981106

AB   IGF-I compns. include a solubilizing compd. comprising a  
guanidinium group that provides for IGF-I compns. in which  
IGF-I is highly sol. at pHs of about 5.5 or greater and at  
refrigerated temps.   IGF-I was formulated with arginine for injection.

REFERENCE COUNT:    4    THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 17:12:44 ON 27 JAN 2004)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA' ENTERED AT  
17:13:39 ON 27 JAN 2004

L1    86011 S (INSULIN-LIKE GROWTH FACTOR-1) OR IGF-I

L2    3034 S COMPOSITION (P) L1

L3    73 S SOLUBILIZING COMPOUND

L4    368475 S ARGININE OR (GUANIDINE HYDROCHLORIDE) OR N-ACETYL-ARGININE OR

L5    1 S L2 (P) L4 (P) SOLUBILIZING

=> s l2 (p) l3

L6    1 L2 (P) L3

=> s l6 not l5

L7    0 L6 NOT L5

=> s l2 (p) pH (p) mg/ml

'ML' IS NOT A VALID FIELD CODE

'ML' IS NOT A VALID FIELD CODE

'ML' IS NOT A VALID FIELD CODE

'ML' IS NOT A VALID FIELD CODE

L8    0 L2 (P) PH (P) MG/ML

=> s buffer (p) ph (p) l2

L9    1 BUFFER (P) PH (P) L2

=> s l9 not l5

L10 1 L9 NOT L5

=> d l10 1 ibib abs

L10 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1998:124031 CAPLUS

DOCUMENT NUMBER: 128:188629

TITLE: Composition comprising insulin and insulin-like growth factor-I (IGF-I)

INVENTOR(S): Clark, Ross G.; Oeswein, James Q.; Yeung, Douglas A.

PATENT ASSIGNEE(S): Genentech, Inc., USA

SOURCE: PCT Int. Appl., 56 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9806423	A1	19980219	WO 1997-US13566	19970731
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5783556	A	19980721	US 1996-696314	19960813
ZA 9706598	A	19990217	ZA 1997-6598	19970724
CA 2261799	AA	19980219	CA 1997-2261799	19970731
AU 9738243	A1	19980306	AU 1997-38243	19970731
AU 731745	B2	20010405		
EP 918536	A1	19990602	EP 1997-935259	19970731
EP 918536	B1	20010919		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2000516229	T2	20001205	JP 1998-509799	19970731
EP 1114644	A1	20010711	EP 2001-106315	19970731
EP 1114644	B1	20020814		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
AT 205722	E	20011015	AT 1997-935259	19970731
ES 2162321	T3	20011216	ES 1997-935259	19970731
PT 918536	T	20020328	PT 1997-97935259	19970731
AT 222120	E	20020815	AT 2001-106315	19970731
PT 1114644	T	20021231	PT 2001-1106315	19970731
ES 2180523	T3	20030216	ES 2001-106315	19970731
AU 752411	B2	20020919	AU 2000-72263	20001214
PRIORITY APPLN. INFO.: US 1996-696314 A 19960813				
EP 1997-935259 A3 19970731				
WO 1997-US13566 W 19970731				

AB Formulations contg. NPH insulin are useful for treating hyperglycemic disorders, such as diabetes, in a mammal in need of treatment. One such formulation, which is preferably administered parenterally, more preferably by injection, comprises IGF-I and NPH insulin, in amts. of from or about 1 to 10 mg IGF-I and from or about 0.2 to 2 mg NPH insulin in a pharmaceutically acceptable carrier. Another such formulation comprises IGF-I and NPH insulin in an acetic acid salt buffer. Still another formulation comprises IGF-I and NPH insulin in a wt. ratio of NPH insulin to IGF-I of from or about 10:1 to 1:50 (wt./wt.), from or about 0.05 to 0.3 M of an osmolyte, from or about 0.1 to 10 mg/mL of a stabilizer, and from or about 5 to 100 mM of a buffer at from or about pH 5 to 7. A still further compn. comprises NPH insulin in an acetic acid salt buffer.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> his

HIS IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.

For a list of commands available to you in the current file, enter

"HELP COMMANDS" at an arrow prompt (=>).

=> s (glutaric acid) or (maleic acid) or (succinic acid) or (citric acid) or imidazole or histidine

3 FILES SEARCHED...

5 FILES SEARCHED...

L11 450482 (GLUTARIC ACID) OR (MALEIC ACID) OR (SUCCINIC ACID) OR (CITRIC ACID) OR IMIDAZOLE OR HISTIDINE

=> s l11 (p) buffer

L12 11680 L11 (P) BUFFER

=> d his

(FILE 'HOME' ENTERED AT 17:12:44 ON 27 JAN 2004)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA' ENTERED AT 17:13:39 ON 27 JAN 2004

L1 86011 S (INSULIN-LIKE GROWTH FACTOR-1) OR IGF-I  
L2 3034 S COMPOSITION (P) L1  
L3 73 S SOLUBILIZING COMPOUND  
L4 368475 S ARGININE OR (GUANIDINE HYDROCHLORIDE) OR N-ACETYL-ARGININE OR  
L5 1 S L2 (P) L4 (P) SOLUBILIZING  
L6 1 S L2 (P) L3  
L7 0 S L6 NOT L5  
L8 0 S L2 (P) PH (P) MG/ML  
L9 1 S BUFFER (P) PH (P) L2  
L10 1 S L9 NOT L5  
L11 450482 S (GLUTARIC ACID) OR (MALEIC ACID) OR (SUCCINIC ACID) OR (CITRIC  
L12 11680 S L11 (P) BUFFER

=> s l2 (p) l12

L13 1 L2 (P) L12

=> s l13 not l9

L14 1 L13 NOT L9

=> s l14 not l5

L15 0 L14 NOT L5

=> s shirley b?/au

L16 328 SHIRLEY B?/AU

=> s bajwa k?/au

L17 40 BAJWA K?/AU

=> s (l16 or l17) and l2

L18 2 (L16 OR L17) AND L2

=> duplicate remove l18

PROCESSING COMPLETED FOR L18

L19 2 DUPLICATE REMOVE L18 (0 DUPLICATES REMOVED)

=> d l18 1-2 ibib abs

L18 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1999:325815 CAPLUS

DOCUMENT NUMBER: 130:343031

TITLE: Compositions providing for increased IGF-I solubility

INVENTOR(S): Shirley, Bret A.; Bajwa, Kamaljit

PATENT ASSIGNEE(S): Chiron Corporation, USA

SOURCE: PCT Int. Appl., 32 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

WO 9924063	A1	19990520	WO 1998-US23673	19981106
------------	----	----------	-----------------	----------

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 9915193	A1	19990531	AU 1999-15193	19981106
------------	----	----------	---------------	----------

EP 1028748	A1	20000823	EP 1998-959383	19981106
------------	----	----------	----------------	----------

EP 1028748	B1	20030502		
------------	----	----------	--	--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI

JP 2001522814	T2	20011120	JP 2000-520151	19981106
---------------	----	----------	----------------	----------

AT 238807	E	20030515	AT 1998-959383	19981106
-----------	---	----------	----------------	----------

PRIORITY APPLN. INFO.: US 1997-64891P P 19971107

WO 1998-US23673 W 19981106

AB IGF-I compns. include a solubilizing compd. comprising a guanidinium group that provides for IGF-I compns. in which IGF-I is highly



sol. at pHs of about 5.5 or greater and at refrigerated temps. IGF-I was formulated with arginine for injection.  
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1999:325814 CAPLUS  
DOCUMENT NUMBER: 130:343030  
TITLE: Human IGF-I syrup composition and its use  
INVENTOR(S): Shirley, Bret A.; Hora, Maninder S.  
PATENT ASSIGNEE(S): Chiron Corporation, USA  
SOURCE: PCT Int. Appl., 34 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 3  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9924062	A1	19990520	WO 1998-US23672	19981106
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DE, DK, DK, EE, EE, ES, FI, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9913847	A1	19990531	AU 1999-13847	19981106
EP 1028747	A1	20000823	EP 1998-957637	19981106
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2001522813	T2	20011120	JP 2000-520150	19981106
US 2003109427	A1	20030612	US 1998-187661	19981106
PRIORITY APPLN. INFO.: US 1997-64891P P 19971107				
US 1998-96081P P 19980811				
WO 1998-US23672 W 19981106				

AB A highly concd., low salt-contg., biol. active syrup form of IGF-I or variant thereof and methods for its prepn. are provided. This novel syrup form of IGF-I has an IGF-I concn. of at least about 250 mg/mL, a d. of about 1.0 g/mL to about 1.2 g/mL, and a viscosity of about 13,000 cP (cps) to about 19,000 cps, as measured at ambient temp. (23 °C). The IGF-I syrup is prepd. by pptg. or partitioning IGF-I from soln., preferably by adjusting the soln. pH or by use of a soly. enhancer to conc. IGF-I in soln. followed by removal of the soly. enhancer. The pptd. syrup is useful as a means of storing IGF-I in a stable form and as a means of prepg. compns. comprising biol. active IGF-I. Pharmaceutical compns. and kits comprising this concd. IGF-I syrup are provided. The pptd. IGF-I syrup, IGF-I reconstituted from the IGF-I syrup, pharmaceutical compns., and kits are useful in IGF-I therapy directed to IGF-I-responsive conditions.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 17:12:44 ON 27 JAN 2004)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA' ENTERED AT  
17:13:39 ON 27 JAN 2004

L1 86011 S (INSULIN-LIKE GROWTH FACTOR-1) OR IGF-I  
L2 3034 S COMPOSITION (P) L1  
L3 73 S SOLUBILIZING COMPOUND  
L4 368475 S ARGININE OR (GUANIDINE HYDROCHLORIDE) OR N-ACETYL-ARGININE OR  
L5 1 S L2 (P) L4 (P) SOLUBILIZING  
L6 1 S L2 (P) L3  
L7 0 S L6 NOT L5  
L8 0 S L2 (P) PH (P) MG/ML  
L9 1 S BUFFER (P) PH (P) L2  
L10 1 S L9 NOT L5  
L11 450482 S (GLUTARIC ACID) OR (MALEIC ACID)OR (SUCCINIC ACID) OR (CITRIC  
L12 11680 S L11 (P) BUFFER  
L13 1 S L2 (P) L12  
L14 1 S L13 NOT L9  
L15 0 S L14 NOT L5  
L16 328 S SHIRLEY B?/AU  
L17 40 S BAJWA K?/AU  
L18 2 S (L16 OR L17) AND L2  
L19 2 DUPLICATE REMOVE L18 (0 DUPLICATES REMOVED)

=> log y

COST IN U.S. DOLLARS	ENTRY	SINCE FILE SESSION	TOTAL
FULL ESTIMATED COST		90.67	91.09

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	ENTRY	SINCE FILE SESSION	TOTAL
CA SUBSCRIBER PRICE		-2.77	-2.77

STN INTERNATIONAL LOGOFF AT 17:24:44 ON 27 JAN 2004